Accordingly, monoclonal antibodies inhibit KIR2DL5 interaction with PVR reduced tumor growth in several humanized tumor models [124], suggesting the blockade of the KIR2DL5/PVR interaction as a novel method of immunotherapy for treating human cancers. This evidence concerns the gene PVR and neoplasm.